Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2014

View Archived Issues

Covagen presents novel bispecific anti-CD3/EGFR FynomAbs with excellent antitumor activity

Amgen reveals promising preclinical data for the oncolytic antibody candidate AMG-780

Acerta Pharma presents preclinical data for ACP-196

New bicyclic derivatives synthesized by Roche

Dainippon Sumitomo Pharma patents new alpha7 nAChR modulators

Johnson & Johnson reviews regulatory progress of first quarter 2014

Daclatasvir/asunaprevir/BMS-791325 combination evaluated in genotype 4 HCV

World Malaria Day: Discovery of novel vaccines and repurposing of existing drugs

Mitomycin C gel formulation may enhance topical efficacy in urothelial cancer

New agents for diabetes patented by Eli Lilly

Dana-Farber Cancer Institute designs novel MAbs for cancer and viral infections

Allergan discloses novel lysophospholipid receptor ligands

Immatics to continue developing IMA-950 vaccine for glioblastoma

Bayer seeks approval for riociguat for pulmonary arterial hypertension in Japan

Phase II study of selinexor begins in patients with advanced gynecologic malignancies

Hydra Biosciences and Boehringer Ingelheim to develop drugs for CNS disorders

Cynapsus reports results of APL-130277 trial in Parkinson's disease

Roche initiates phase I study of RO-6839921 for advanced cancers and AML

Biogen Idec and Quintiles form clinical development partnership

Medivir and HemoShear form collaboration

Amgen to study AMG-232 for metastatic cutaneous melanoma

Kyowa Hakko Kirin reflects on accomplishments of first quarter 2014

MedImmune advances RSV pipeline

Zogenix to sell Sumavel DosePro to Endo

Safety issues lead to discontinuation of nimotuzumab trial in lung cancer in Japan

Roche's cobas HPV Test approved in U.S. for first-line primary screening for cervical cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...